Clinical trials: Allogeneic Stem Cell Transplantation
Acute Graft Versus Host Disease
A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant
This study is to establish the safety, determine if there is an improvement in steroid refractory acute graft-vs-host disease (aGvHD) compared to historical cohorts, and determine the changes of aGvHD-associated T-cell clones in…
- Trial name
- NCT02436460
- Testing
- AbGn-168H
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer
Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor (CPI) pembrolizumab.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
- Trial name
- ILIAD (NCT03735290)
- Testing
- ilixadencel, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Mendus
Retinitis Pigmentosa
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells.
- Trial name
- NCT05909488
- Testing
- 1.5 x 10^6 UC-MSC + CM, 5 x 10^6 UC-MSC + CM
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Burn
A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound
This is a phase I study to evaluate the safety of ALLO-ASC-DFU for the treatment of deep second-degree burn wound patients. ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells.
- Trial name
- NCT02394873
- Testing
- ALLO-ASC-DFU
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- Anterogen Co., Ltd.
Covid19
Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress
This is a Phase 2 randomized controlled study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care treatments for COVID-19 infection in hospitalized subjects with acute respiratory distress…
- Trial name
- NCT04903327
- Testing
- COVI-MSC
- Where
- 6 sites in Brazil
- Volunteers
- 43 people
- Sponsor
- Sorrento Therapeutics, Inc.
Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma
Long-Term Follow-up Study
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT.
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- LTFS (NCT05332054)
- Testing
- Caribou-sponsored investigational therapy
- Where
- 31 sites in United States
- Volunteers
- 150 people
- Sponsor
- Caribou Biosciences, Inc.
Chronic Graft Versus Host Disease
Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
The primary objective of this study is to evaluate the effect of entospletinib (ENTO) on the best overall response rate in adults with chronic graft versus host disease (cGVHD) who are currently receiving systemic corticosteroids…
- Trial name
- NCT02701634
- Testing
- ENTO
- Where
- 30 sites in United States, Canada and 5 more
- Volunteers
- 66 people
- Sponsor
- Gilead Sciences
Type 1 Diabetes
A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD13-02 in patients with aT1DM
- Trial name
- NCT07142161
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Acute Myelogenous Leukemia
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
The primary objective of this study is to evaluate the safety of gemtuzumab ozogamicin in relapsed CD33-positive AML patients who received HSCT. If the MTD dose is not reached, 9 mg/m2 will be the maximum tested dose.
- Trial name
- NCT00044733
- Testing
- Mylotarg (gemtuzumab ozogamicin) Injection
- Where
- 13 sites in United States
- Volunteers
- 38 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
AML/MDS, CD33 Expressing Hematological Malignancies
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
- Conditions
- AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
- Trial name
- NCT06325748
- Testing
- SENTI-202
- Where
- 8 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Senti Biosciences
Diabetes Mellitus, Diabetes Mellitus, Type 1
An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D
This is an open-label, multicenter, Phase 1 study evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects with T1D
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- NCT05565248
- Testing
- VCTX211
- Where
- 2 sites in Canada
- Volunteers
- 5 people
- Sponsor
- CRISPR Therapeutics AG
Covid19
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise
This is a Phase 2a randomized, placebo-controlled study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 "long haul" pulmonary compromise.
- Trial name
- BR (NCT04992247)
- Testing
- COVI-MSC
- Sponsor
- Sorrento Therapeutics, Inc.
Acute Myeloid Leukaemia
Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia
This is a Phase I, open-label, dose escalation study of UCART123 administered intravenously to patients with newly diagnosed CD123 positive adverse genetic risk acute myeloid leukaemia (AML) defined in the ELN adverse genetic…
- Trial name
- NCT04106076
- Testing
- UCART123
- Sponsor
- Cellectis S.A.
Cytomegalovirus (CMV)-Positive Recipients, Allogeneic, Hematopoietic Cell Transplant (HCT)
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
The purpose of the study was to evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through 1 year post-transplant.
- Trial name
- HELIOS (NCT01877655)
- Testing
- ASP0113
- Where
- 83 sites in United States, Australia and 9 more
- Volunteers
- 514 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory…
- Conditions
- Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05020678
- Testing
- NKX019
- Where
- 6 sites in United States, Australia
- Volunteers
- 150 people
- Sponsor
- Nkarta, Inc.
Breast Cancer
Vaccine Treatment for Advanced Breast Cancer
This 2-phase study will determine the safety of treating patients with breast cancer with the genetically engineered HyperAcute-Breast cancer vaccine.
- Trial name
- NCT00090480
- Testing
- HyperAcute - Breast cancer vaccine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NewLink Genetics Corporation
Keloid
Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid
The clinical trial will be carried out at the Gatot Soebroto Army Central Hospital, Jakarta and planned from June 2020 to December 2020.
- Trial name
- Keloid (NCT04326959)
- Testing
- Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium, Conditioned Medium, Triamcinolone Acetonide
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PT. Prodia Stem Cell Indonesia
Gingival Recession
A Pilot Clinical Trial of Gintuit (TM)in Establishing a Functional Zone of Attached Gingiva
The purpose of this study is to evaluate the safety and efficacy of Gintuit compared to a free autogenous graft using donor tissue harvested from the subject's palate in the treatment of subjects who have an insufficient zone of…
- Trial name
- NCT01547962
- Testing
- Gintuit, autologous Free Gingival Graft (FGG)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Organogenesis
Ankylosing Spondylitis
Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Ankylosing Spondylitis
The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with Ankylosing Spondylitis, and to further explore the efficacy…
- Trial name
- NCT05962762
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells
- Volunteers
- 9 people
- Sponsor
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
Acute-On-Chronic Liver Failure
Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure
This is an interventional, single arm, multicenter, phase I/IIa clinical trial. The study objective is to investigate the efficacy and safety of three i.v.
- Trial name
- NCT03860155
- Testing
- allo-APZ2-ACLF
- Where
- 5 sites in Germany
- Volunteers
- 5 people
- Sponsor
- RHEACELL GmbH & Co. KG